CanBas Co., Ltd.

4575

JP3244570002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-10 EDT			5-day change	1st Jan Change
461 ^JPY	+0.44%		0.00%	-51.98%

2023	CanBas Co., Ltd.(TSE:4575) added to S&P Global BMI Index	CI
2023	CanBas Co., Ltd. announced that it has received ¥748.0425 million in funding	CI

CanBas Co., Ltd. announced that it has received ¥754.278462 million in funding

October 30, 2019

On October 31, 2019, CanBas Co., Ltd. (TSE:4575) closed the transaction.

Latest news about CanBas Co., Ltd.

CanBas Co., Ltd.(TSE:4575) added to S&P Global BMI Index	23-09-18	CI
CanBas Co., Ltd. announced that it has received ¥748.0425 million in funding	23-06-01	CI
CanBas Co., Ltd. announced that it expects to receive ¥748.0425 million in funding	23-05-17	CI
CanBas Co., Ltd. announced that it has received ¥16.38843 million in funding from Inflexion Partners, and another investor	21-09-28	CI
CanBas Co., Ltd. announced that it expects to receive ¥16.38843 million in funding	21-09-01	CI
CanBas Co., Ltd. announced that it expects to receive ¥9.678321 million in funding from Advantage Partners, Inc. and other investors	20-11-04	CI
CanBas Co., Ltd. announced that it has received ¥754.278462 million in funding	19-10-30	CI
CanBas Co., Ltd. announced that it expects to receive ¥754.278462 million in funding	19-10-09	CI
CanBas Co., Ltd. announced that it has received ¥210.17 million in funding from Milestone Capital Management Co., Ltd.	18-07-17	CI
CanBas Co., Ltd. announced that it expects to receive ¥209.2 million in funding from Milestone Capital Management Co., Ltd.	18-07-01	CI
CanBas Co., Ltd. Enters into Research Agreement with Fujifilm Corp	17-06-27	CI
CanBas Co., Ltd. announced that it has received ¥7.15 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm.	15-07-08	CI
CanBas Co., Ltd. announced that it expects to receive ¥7.15 million in funding from Merrill Lynch Japan Securities Co., Ltd., Investment Arm.	15-06-21	CI
Stemline Therapeutics, Inc. Announces Exclusive License from Canbas Co., Ltd	15-01-07	CI
CanBas Co., Ltd. announced that it has received ¥109.66 million in funding from Milestone Capital Management Co., Ltd.	13-12-01	CI
CanBas Co., Ltd. announced that it expects to receive ¥104.70 million in funding.	13-11-13	CI
CanBas Co., Ltd. announced that it has received ¥1.50 million in funding from Milestone Capital Management Co., Ltd.	12-08-27	CI

CanBas Co Ltd is a Japan-based company mainly engaged in drug development and research. The company is mainly engaged in the basic anticancer drug discovery research (including development of drug discovery concepts, selection of drug candidate compounds using methods based on these concept developments, simple animal studies, and collection and analysis of basic data on anticancer drug candidates that have entered development) and early clinical development (including preclinical studies prior to submission of applications to start clinical trials and the first part of clinical trials).

Sector

Pharmaceuticals

Calendar

2024-05-09 - Q3 2024 Earnings Release

More about the company

	1st Jan change	Capi.
CANBAS CO., LTD.	-51.98%	53.16M
MERCK KGAA	+7.70%	72.94B
KYOWA KIRIN CO. LTD.	+12.64%	9.06B
SK BIOPHARMACEUTICALS CO., LTD.	-10.56%	5.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+58.79%	4.78B
YUHAN CORPORATION	+4.07%	3.9B
BETTA PHARMACEUTICALS CO., LTD.	-16.90%	2.56B
INDIVIOR PLC	+21.10%	2.42B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-26.13%	2.39B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.31%	2.18B

Specialty & Advanced Pharmaceuticals

CanBas Co., Ltd.

Equities

4575

JP3244570002

Pharmaceuticals

CanBas Co., Ltd. announced that it has received ¥754.278462 million in funding

Latest news about CanBas Co., Ltd.

Chart CanBas Co., Ltd.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Specialty & Advanced Pharmaceuticals